Status:
COMPLETED
Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar®
Lead Sponsor:
Region Skane
Collaborating Sponsors:
Lund University
Conditions:
Rheumatoid Arthritis
Spondylarthropathy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Previous studies have analyzed serological responses following pneumococcal vaccination using 23-valent vaccination (Pneumovax) in Rheumatoid Arthritis (RA) patients that were on different therapeutic...
Detailed Description
Background: Previous studies have analyzed serological responses following pneumococcal vaccination using 23-valent vaccination (Pneumovax) in Rheumatoid Arthritis (RA) patients that were on different...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Clinical diagnosis of RA or spondylarthropathy
Exclusion
- Pregnancy
- Allergy
- Has received pneumococcal vaccination within 5 years
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
505 Patients enrolled
Trial Details
Trial ID
NCT00828997
Start Date
August 1 2008
End Date
January 1 2018
Last Update
December 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lund, Sweden